Drugs / HLX51
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05788107 | Jun 2024 → May 2025 overdue | adult lymphoma | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-03-15 | Shanghai Henlius Biotech | Regulatory Henlius Novel anti-OX40 HLX51 Received Clinical Trial Approval in China henlius.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-03-15 | Shanghai Henlius Biotech | Henlius Novel anti-OX40 HLX51 Received Clinical Trial Approval in China henlius.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX51 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05788107 ↗ |
| Action | Activate | “anti-OX40 tetravalent agonistic humanized monoclonal antibody” NCT05788107 ↗ |
| Modality | Monoclonal antibody | “anti-OX40 tetravalent agonistic humanized monoclonal antibody” NCT05788107 ↗ |
| Route | Intravenous | “Patients will be given different doses of HLX51 intravenously.” NCT05788107 ↗ |